Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
Showing 141 - 160 results of 21,342 for search '(( significant ((greater decrease) OR (mean decrease)) ) OR ( significant decrease decrease ))', query time: 0.73s Refine Results
  1. 141
    Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells.

    Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells. by Courtney A. Swain (15170264)

    Published 2025
    Save to List
    Saved in:
  2. 142
    Networks favouring more connected individuals results in a significant decrease to the likelihood of network recovery.

    Networks favouring more connected individuals results in a significant decrease to the likelihood of network recovery. by Adam Lee Miles (14123916)

    Published 2024
    Save to List
    Saved in:
  3. 143
    Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism.

    Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism. by María Gallardo-Campos (22170919)

    Published 2025
    Save to List
    Saved in:
  4. 144
    Mean KAP scores and standard deviation at different assessment times.

    Mean KAP scores and standard deviation at different assessment times. by Chikondi Maluwa (20660522)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 145
    No significant diurnal rhythmicity of short chain fatty acids in the blood was observed.

    No significant diurnal rhythmicity of short chain fatty acids in the blood was observed. by Weiran Shan (16969688)

    Published 2025
    Save to List
    Saved in:
  6. 146
    The mean and standard deviation of outcome measures.

    The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 147
    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>

    Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

    Published 2025
    “…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
    Save to List
    Saved in:
  8. 148
    RcbA and RcbB co-operatively decrease motility independent of CaCl<sub>2</sub> concentration.

    RcbA and RcbB co-operatively decrease motility independent of CaCl<sub>2</sub> concentration. by Shobnom Mustaree (21728815)

    Published 2025
    Save to List
    Saved in:
  9. 149
    Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon.

    Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

    Published 2025
    Save to List
    Saved in:
  10. 150
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 151
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 152
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 153
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 154
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 155
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 156
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 157
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 158
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 159
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 160
    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU.

    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

    Published 2025
    Save to List
    Saved in:

Search Tools: